STRONGkids nutrition screening tool in pediatrics: An analysis of cutoff points in Brazil

Joice da Silva Castro1, Carolina Araújo Dos Santos1, Carla de Oliveira Barbosa Rosa1

  • 1Department of Nutrition and Health, Federal University of Viçosa, Viçosa, Minas Gerais, Brazil.

Insights

The STRONGkids screening tool effectively identifies pediatric nutrition risk in Brazil. A modified cutoff is proposed, classifying 3 points as high risk to better predict prolonged hospital stays.

Area of Science:

  • Pediatric Nutrition
  • Clinical Assessment
  • Healthcare Management

Background:

  • The STRONGkids tool is validated for pediatric nutrition screening in hospitals.
  • Its original cutoff values require evaluation for applicability in the Brazilian context.

Purpose of the Study:

  • To assess the suitability of STRONGkids cutoff values in Brazil.
  • To determine STRONGkids' ability to predict malnutrition and extended hospital stays.

Main Methods:

  • Cross-sectional study in a Brazilian public hospital pediatric ward.
  • STRONGkids used for nutrition risk assessment; malnutrition identified via anthropometric indexes.
  • Receiver operating characteristic curves analyzed to evaluate STRONGkids' predictive capacity.

Main Results:

  • Included 599 pediatric patients; 83.6% had medium or high nutrition risk.
  • STRONGkids uniquely identified patients with longer hospital stays.
  • Patients scoring 3 on STRONGkids showed similar hospitalization patterns to those with high risk (4-5 points).

Conclusions:

  • For prolonged hospitalization prediction in Brazil, STRONGkids should classify 3 points as high nutrition risk.
  • This adjustment enhances the tool's utility in the Brazilian pediatric population.
  • The findings support optimizing STRONGkids for local healthcare needs.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
27
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
18
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
19
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
32